Sanofi has stopped a phase 2 trial of Denali Therapeutics-partnered oditras | Sanofi has stopped a phase 2 trial of the ...

Upstream Bio has swollen its IPO to $255 million as the company joins CAMP4 Therapeutics this morning in becoming the latest ...

Difficult. Impossible. Agonizing. Worse than voting in the national election. | Difficult. Impossible. Agonizing. Worse than ...

Booster Therapeutics has launched with $15 million in seed financing and a mission to take on the current crop of targeted ...

The digital diabetes developer Glooko has collected $100 million and a new CEO to help boost the trajectory of its data ...

Ono Pharmaceutical has bought a seat in a quiet corner of the congested antibody-drug conjugate (ADC) space, agreeing | Ono ...

Cytovale has raised $100 million in venture capital funding to support its rapid test for determining a patient’s sepsis risk ...

Immatics has vaulted into phase 3 on the strength of early-stage data. The biotech is gearing up to start a pivotal trial of ...

To find RNA viruses hiding in genomic “dark matter,” researchers took advantage of one thing they all have in common: the RNA polymerase enzyme.

Gritstone bio may have left no stone unturned when it came to searching for a financial rescue, but the vaccine biotech has ...

Some six years after picking up Seattle’s Universal Cells for $102 million, Astellas Pharma is opening a second location for ...

London-based biotech Purespring Therapeutics plans to bring their kidney-tweaking gene therapy to the clinic with the help of ...